Organon & Co. (OGN) Set to Post Quarterly Earnings on Monday

Organon & Co. (NYSE:OGN) will likely be posting its Q3 2026 resultson Monday, November 9th. Analysts expect the company to post earnings of $0.88 per share and revenue of $1.58 billion for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, October 30, 2026 at 7:00 AM ET.

Organon & Co. Stock Down 0.0%

Shares of Organon & Co. stock opened at $13.84 on Monday. The firm has a market cap of $3.63 billion, a PE ratio of 18.20, a P/E/G ratio of 1.27 and a beta of 1.53. The business’s 50 day simple moving average is $13.74 and its 200 day simple moving average is $11.47. The company has a debt-to-equity ratio of 8.43, a quick ratio of 1.44 and a current ratio of 1.95. Organon & Co. has a 52-week low of $5.69 and a 52-week high of $13.84.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Monday, November 9th will be issued a $0.02 dividend. The ex-dividend date is Monday, November 9th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. Organon & Co.’s dividend payout ratio (DPR) is 10.39%.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Five investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Reduce” and an average target price of $11.40.

Organon & Co. Company Profile

Organon & Co is a global health care company focused on improving the health and quality of life of women throughout their lives. The company develops, manufactures and commercializes prescription medicines and other health care products, with operations serving patients and health care providers in markets around the world.

Organon’s women’s health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as medicines and technologies related to fertility, pregnancy and other reproductive health needs.